Related Experiment Video

Updated: Jul 28, 2026

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
08:03

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes

Published on: June 25, 2017

Glucose-dependent insulinotropic effects of JTT-608, a novel antidiabetic compound

N Furukawa1, T Ohta, T Noguchi

  • 1Japan Tobacco, Central Pharmaceutical Research Institute, Takatsuki, Osaka.

European Journal of Pharmacology
|June 4, 1999
PubMed

Insights

JTT-608, a novel antidiabetic compound, enhances insulin secretion, particularly at high glucose levels. It acts differently from sulphonylureas, offering a new therapeutic approach for diabetes.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Cell Biology

Background:

  • Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance and impaired insulin secretion.
  • Novel therapeutic agents are needed to improve glycemic control by enhancing insulin secretion.
  • Understanding the mechanisms of insulin secretagogues is crucial for developing effective antidiabetic drugs.

Purpose of the Study:

  • To investigate the effects of JTT-608, a novel antidiabetic compound, on insulin secretion.
  • To elucidate the mechanism of action of JTT-608 in comparison to sulphonylureas.
  • To evaluate the efficacy of JTT-608 in preclinical models of diabetes.

Main Methods:

  • Experiments were conducted using mouse insulinoma (MIN6) cells and isolated, perfused rat pancreas.
  • Insulin secretion was measured in response to varying glucose concentrations and JTT-608 doses.
  • [3H]glibenclamide binding assays were performed to assess interaction with K+-ATP channels.
  • Studies included normal rats and neonatally streptozotocin-induced non-insulin-dependent diabetes mellitus (nSTZ) rats.

Main Results:

  • JTT-608 dose-dependently enhanced insulin secretion in MIN6 cells and perfused rat pancreas.
  • Enhancement was glucose concentration-dependent, with potent effects at high glucose levels.
  • JTT-608 stimulated insulin secretion independently of K+-ATP channels and did not inhibit glibenclamide binding.
  • In nSTZ rats, JTT-608 normalized first-phase and doubled second-phase insulin secretion.

Conclusions:

  • JTT-608 is a novel insulin secretagogue with a distinct mechanism of action compared to sulphonylureas.
  • Its glucose-dependent insulin-enhancing properties suggest potential for safe and effective T2DM treatment.
  • JTT-608 represents a promising therapeutic candidate for managing diabetes by improving beta-cell function.

More Related Videos

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)

Published on: January 7, 2018

An In Ovo Model for Testing Insulin-mimetic Compounds06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Related Concept Videos

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...